Cover Image

SGLT-2 inhibitors: Post infarction interventional effects

Saved in:

Bibliographic Details
Main Authors:	Pugazhenthan Thangaraju (Author), Krishnapriya Neelambaran (Author), Hemasri Velmurugan (Author)
Format:	Book
Published:	Elsevier, 2023-03-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Time to be vigilant in contacts of leprosy for possible single-dose rifampicin
by: Pugazhenthan Thangaraju, MD, et al.
Published: (2022)

Reply to SGLT-2 inhibitors: Post-infarction interventional effects
by: Pasquale Paolisso, et al.
Published: (2023)

Drug flibanserin-in hypoactive sexual desire disorder
by: Pugazhenthan Thangaraju, et al.
Published: (2022)

Mechanistic evaluation of the inhibitory effect of four SGLT-2 inhibitors on SGLT 1 and SGLT 2 using physiologically based pharmacokinetic (PBPK) modeling approaches
by: Yu Zhang, et al.
Published: (2023)

SGLT2-inhibitors are effective and safe in the elderly: The SOLD study
by: Maria Elena Lunati, et al.
Published: (2022)

Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis
by: Zofia Wicik, et al.
Published: (2022)

SGLT-2 inhibitors: new effective drugs for treatment of heart failure
by: Olgierd Król, et al.
Published: (2022)

The use of SGLT2 inhibitors in the treatment of cognitive disorders
by: Marta Lato, et al.
Published: (2023)

SGLT2 Inhibitors and Fracture Risk in Elderly Population
by: Vishal R Tandon, et al.
Published: (2023)

SGLT2 inhibitors and the changing landscape for treatment of diabetes
by: Liu S, et al.
Published: (2019)

SGLT2 inhibitors: control of glycemia and nephroprotection properties
by: A. A. Volodin, et al.
Published: (2018)

SGLT2 inhibitors: suggestions from the amphibian world
by: Stefano Michelassi
Published: (2022)

Safety and Efficacy of Early SGLT2 Inhibitors Initiation in Diabetic Patients Following Acute Myocardial Infarction, a Retrospective Study
by: Gassan Moady MD, et al.
Published: (2024)

SGLT2-Inhibitors - significant role in Heart Failure treatment
by: Karol Wielgus, et al.
Published: (2024)

Emergence of SGLT2 Inhibitors as Powerful Antioxidants in Human Diseases
by: Kai-Fan Tsai, et al.
Published: (2021)

Bibliometric and visual analysis of SGLT2 inhibitors in cardiovascular diseases
by: Runfang Pan, et al.
Published: (2024)

SGLT-2 inhibitors in the management of acute decompensated heart failure
by: Anastasia E. Poskakalova, et al.
Published: (2024)

Update on developments with SGLT2 inhibitors in the management of type 2 diabetes
by: Nauck MA
Published: (2014)

SGLT2 inhibitors for patients with type 2 diabetes mellitus after myocardial infarction: a nationwide observation registry study from SWEDEHEARTResearch in context
by: Hans Christian Rosén, et al.
Published: (2024)

SGLT2 inhibitors for treatment of Type 2 diabetes mellitus: Focus on Canagliflozin
by: Santosh Kumar Singh, et al.
Published: (2014)

SGLT2 inhibitors for treatment of Type 2 diabetes mellitus: Focus on Canagliflozin
by: Santosh Kumar Singh, et al.
Published: (2014)

Use of SGLT-2 Inhibitors in Patients With Type 1 Diabetes Mellitus
by: Lea El Hage MD, et al.
Published: (2019)

The Importance of SGLT-2 Inhibitors as Both the Prevention and the Treatment of Diabetic Cardiomyopathy
by: Klaudia Kowalska, et al.
Published: (2022)

Analysis of efficacy of SGLT2 inhibitors using semi-mechanistic model
by: Oleg eDemin Jr, et al.
Published: (2014)

Ketoacidosis as unexpected adverse reaction SGLT<sub>2</sub> inhibitor
by: T. M. Bukatina, et al.
Published: (2018)

The Role of SGLT2 Inhibitors in Atherosclerosis: A Narrative Mini-Review
by: Aurélie Pahud de Mortanges, et al.
Published: (2021)

Evolving Clinical Features of Diabetic Ketoacidosis: The Impact of SGLT2 Inhibitors
by: Selin Genc, et al.
Published: (2024)

Effects of SGLT2 inhibitor dapagliflozin in patients with type 2 diabetes on skeletal muscle cellular metabolism
by: Yvo J.M. op den Kamp, et al.
Published: (2022)

COVID-19: Wait for a novel drug or act with the age old drug - Do we have a choice?
by: Pugazhenthan Thangaraju, et al.
Published: (2020)

SGLT-2 Inhibitors in Kidney Transplant Recipients: Our Story So Far
by: Luís Leite de Sousa, et al.
Published: (2023)

Euglycemic diabetes ketoacidosis associated with SGLT-2 inhibitors - review of case reports
by: Joanna Winciorek, et al.
Published: (2024)

SGLT2 Inhibitors: A Novel Player in the Treatment and Prevention of Diabetic Cardiomyopathy
by: Li N, et al.
Published: (2020)

Retrospective analysis of the effect of SGLT-2 inhibitors on renal function in patients with type 2 diabetes in the real world
by: Rongjing Song, et al.
Published: (2024)

Antidiabetic Effects of SGLT2-Selective Inhibitor Ipragliflozin in Streptozotocin-Nicotinamide-Induced Mildly Diabetic Mice
by: Atsuo Tahara, et al.
Published: (2012)

Effect of a SGLT2 inhibitor on the systemic and intrarenal renin-angiotensin system in subtotally nephrectomized rats
by: Lei Li, et al.
Published: (2018)

The SGLT-2 Inhibitor Dapagliflozin Has a Therapeutic Effect on Atherosclerosis in Diabetic ApoE−/− Mice
by: Weiling Leng, et al.
Published: (2016)

Impact of SGLT2 inhibitors treatment on the chronic kidney disease in people with type 2 diabetes
by: Marcin Czarkowski, et al.
Published: (2022)

Profile of Ipragliflozin, an Oral SGLT-2 Inhibitor for the Treatment of Type 2 Diabetes: The Evidence to Date
by: Alkabbani W, et al.
Published: (2021)

Research advances on renoprotective mechanism of SGLT-2 inhibitors in non-diabetic kidney disease
by: Feng Liu, et al.
Published: (2023)

SGLT-2 Inhibitors and Renal Outcomes in Non-Diabetic Patients: A Systematic Review
by: Mariana Silva de Sousa, et al.
Published: (2023)